The FDA decision on Sol-Gel Technologies Ltd.’s (SLGL) Epsolay, an investigational topical cream containing benzoyl peroxide, 5%, for the treatment of papulopustular rosacea is expected on April 26, 2021.Papulopustular rosacea is a chronic, inflammatory condition that primarily affects the face and is often characterized by flushing, redness, inflamed bumps, and pustules. The current treatment options like topical antimicrobials and systemic antibiotics have some limitations like insufficient efficacy resulting in poor adherence, systemic side effects and antibiotic resistance.In two 12-week clinical studies, Epsolay demonstrated statistically significant improvement in both co-primary endpoints namely the number of patients achieving "clear" or "almost clear" in the Investigator Global Assessment and absolute mean reduction from baseline in inflammatory lesion count.If approved, Epsolay is estimated to bring in peak sales of $75 million to $100 million for the company. SLGL closed Friday’s (Mar.26, 2021) trading at $11.32, down 2.58%.